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Abstract
Triple negative tumors are more aggressive than other breast cancer subtypes and there is
a lack of specific therapeutic targets on them. Since muscarinic receptors have been linked
to tumor progression, we investigated the effect of metronomic therapy employing a tradi-
tional anti-cancer drug, paclitaxel plus muscarinic agonists at low doses on this type of
tumor. We observed that MDA-MB231 tumor cells express muscarinic receptors, while they
are absent in the non-tumorigenic MCF-10A cell line, which was used as control. The addi-
tion of carbachol or arecaidine propargyl ester, a non-selective or a selective subtype 2 mus-
carinic receptor agonist respectively, plus paclitaxel reduces cell viability involving a down-
regulation in the expression of ATP “binding cassette” G2 drug transporter and epidermal
growth factor receptor. We also detected an inhibition of tumor cell migration and anti-angio-
genic effects produced by those drug combinations in vitro and in vivo (in NUDE mice)
respectively. Our findings provide substantial evidence about subtype 2 muscarinic recep-
tors as therapeutic targets for the treatment of triple negative tumors.
Introduction
Breast cancer is still the most frequent type of malignancy in women and represents a major
and unsolved problem for public health [1, 2]. Luminal and triple negative (TN) represent the
two opposite ends of the molecular classification of breast tumors and they thoroughly differ
regarding treatment and patients´survival [3]. The TN tumors are typically larger in size,
higher grade than other breast cancers, and they also exhibit an aggressive clinical behavior,
frequently resulting in early metastatic dissemination, particularly to visceral sites. As a result
of these characteristics, TN breast cancers are associated with poor prognosis in comparison to
luminal breast tumors [4, 5]. Considering the treatment of TN tumors, classical modalities
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have improved the overall outlook and quality of life for women with this type of breast cancer.
However, because of recurrence and/or the development of resistance to cytotoxic drugs
administered to patients, produced by a complex mechanism mediated by different types of
proteins such as ATP “binding cassette” (ABC) transporters, a considerable amount of patients
still succumb to this disease highlighting the need to find new therapeutic approaches [6].
Regarding the latter, the administration of low dose chemotherapy with short drug free inter-
vals, named metronomic therapy emerged as a novel regimen for cancer treatment [7]. It
exerts very low incidence of side effects and could add new beneficial actions on immune sys-
tem and tumor microenvironment [8]. This new strategy also needs the identification of new
therapeutic targets to improve the benefits for breast cancer patients.
Non-neuronal cholinergic system (nNCS) has been involved either in physiological or in
pathological processes. The nNCS is formed by acetylcholine (ACh), the enzymes that synthe-
size and degrade ACh and cholinergic receptors expressed in non-neuronal cells. Muscarinic
receptors belong to this group of proteins and have been involved in the progression of differ-
ent type of tumors such as lung, colon and prostate [9–11]. We demonstrated that muscarinic
receptors are expressed in tumor samples from patients with breast cancer in different stages
and also in human MCF-7 cells derived from a luminal, estrogen-dependent adenocarcinoma,
the most frequent type of breast tumor in women [12, 13]. Muscarinic receptors belong to the
G-protein coupled receptors family which constitutes the largest family of cell surface recep-
tors involved in signal transduction. Five subtypes have been identified by molecular cloning:
M1-M5. Their role in the regulation of important cell functions like mitosis, cell morphology,
locomotion and immune response which are key steps during tumor progression has been
documented [14, 15]. The long-term activation of these receptors with the agonist carbachol
stimulates cytotoxicity either in human or in murine breast tumor cells [16, 17]. In the last
years, several reports demonstrated that the activation of subtype 2 muscarinic (M2) receptor
subtype by a selective agonist was able to arrest cell proliferation in different tumor cell lines
[18, 19]. Moreover, M2 receptor activation reduced cell survival, inducing oxidative stress and
severe apoptosis in malignant cells derived from human glioblastoma [20]. MDA-MB231 is a
human cell line derived from a TN breast tumor, which does not express estrogen/progester-
one receptors or HER2 protein.
The aim of our work is to investigate the ability of a combination of paclitaxel (PX) with a
muscarinic agonist both at low doses to inhibit different steps of TN breast tumor progression.
In this work, we identified different subtypes of muscarinic receptors in MDA-MB231 cells by
Western blot, and demonstrated that the combination of PX plus carbachol or arecaidine pro-
pargyl ester (APE), a non-selective or an M2 selective agonist respectively, reduced cell viabil-
ity, migration, vascular endothelial growth factor-A (VEGF-A) expression as well as in vivo
angiogenesis. We also observed a down-regulation in the expression of ABCG2 transporter
and epidermal growth factor receptor (EGFR) in tumor cells by Western blot, after PX plus
carbachol or APE administration revealing that both proteins could be involved in the mecha-
nism of action of this treatment.
Materials and methods
Cell culture
The human breast adenocarcinoma cell line MDA-MB231 (CRM-HTB-26) and MDA-MB468
(HTB-132) were acquired from the American Type Culture Collection (ATCC; Manassas,
USA) and cultured in DMEM (Invitrogen Inc., Carlsbad, USA) with 2 mM L-glutamine and
80 μg/ml gentamycin, supplemented with 10% heat inactivated FBS (Internegocios SA, Mer-
cedes, Argentine) at 37˚C in a humidified 5% CO2 air. The MCF-10A cells (CRL-10317) were
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also bought from ATCC and constitute a non-tumorigenic cell line derived from human mam-
mary tissue. These cells were grown on tissue culture plastic dishes in DMEM:F12(1:1) (Invi-
trogen Inc., Carlsbad, USA) supplemented with 10% FBS, hydrocortisone (0.5 μg/ml), insulin
(10 μg/ml), and hEGF (20 ng/ml). Cell lines were detached using the following buffer: 0.25%
trypsin and 0.02% EDTA in Ca2+ and Mg2+ free PBS from confluent monolayers. The medium
was changed three times a week. Cell viability was determined by Trypan blue exclusion test
and the absence of mycoplasma was observed by Hoechst staining [21].
Detection of muscarinic receptors by Western blot
Cells (2x106) were washed twice with PBS and lysed in 1 ml of 50 mM Tris-HCl, 50 mM NaCl,
5 mM NaF, 5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 5 mM phenylmethanesulfonyl fluoride,
1% Triton X-100 and 10 μg/ml trypsin inhibitor, aprotinin and leupeptin, pH 7.4. Then, lysates
were left 1 h in an ice bath, and later centrifuged at 800 g for 20 min at 4˚C. Supernatants were
saved at -80˚C and protein concentration was analyzed by the method of Bradford [22]. Sam-
ples (80 μg protein per lane) were subjected to 10% SDS-PAGE minigel electrophoresis, trans-
ferred to nitrocellulose membranes, and incubated overnight with goat anti-human M1, M2 or
M3 receptor polyclonal antibodies or rabbit anti-human M4 or M5 receptor polyclonal anti-
bodies (Santa Cruz Biotechnology Inc., USA) all diluted 1:200. Then strips were incubated
with anti-rabbit IgG or anti-goat IgG coupled to horseradish peroxidase, both diluted 1:10000
in 20 mMTris-HCl buffer, 150 mM NaCl and 0.05% Tween 20 (TBS-T) at 37˚C for 1 h. Bands
were visualized by chemiluminescence. The results of densitometric analysis were expressed as
optical density (O.D.) units relative to the expression of glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) (Santa Cruz Biotechnology Inc., USA) [23].
M2 muscarinic receptor silencing
To silence M2 receptors, tumor cells were transfected with four different small interfering
RNA (siRNA) targeting specific sequences of human M2 receptor (ID1129) (Riboxx Life Sci-
ences, Radebeul, Germany). A positive control of transfection Chromo-GAPDH-siRNA
(Riboxx Life Sciences, Radebeul, Germany) and a negative control for siRNA assays (NC-
siRNA) (SI03650318) (Quiagen, Hilden, Germany) were used. The sequences for M2-siRNAs
were the following:
a. (siRNA 1129–1) sense, 5´- AUUUACUACUAAAUCCUCCCCC-3´, antisense 5´-GGGGGA
GGAUUUAGUAGUAAAU-3´;
b. (siRNA 1129–2) sense 5´- AUGUAGCCCAUUUCUUCCCCC-3´, antisense 5´-GGGGGAA
GAAAUGGGCUACAU-3´;
c. (siRNA 1129–3) sense 5´-UCCUUUGAGUUUCAGGCUGCCCCC-3´, antisense 5´- GGGG
GCAGCCUGAAACUCAAAGGA-3´;
d. (siRNA 1129–4) sense 5´-AGUUACACCUUGACCUAACCCCC-3´, antisense 5´-GGGGGU
UAGGUCAAGGUGUAACU-3´.
The cells were seeded in 6-well plates (104 cells/well) and cultured in 2 ml DMEM with 10%
FBS until they were 60–70% confluent. The siRNAs were mixed with Riboxx-Fect according to
manufacturer’s instructions and then added to wells. The efficiency of the transfection was
evaluated by transfecting in separate wells Chromo-GAPDH-siRNA (Riboxx Life Sciences,
Radebeul, Germany). The ability of the siRNA pool to down-regulate M2 muscarinic receptor
expression was tested 72 h after transfection with 40 nM/well of siRNA and evaluated by West-
ern blot detecting M2 receptor protein expression (23).
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Cell viability assay
The inhibition in cell viability exerted by different treatments for one or three cycles of 48h
was analyzed employing the soluble tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) colorimetric assay (Life Technologies, Eugene, USA). When
cells are alive, MTT is reduced to formazan. 4x103cells/well were seeded in 96-well plates in
culture medium supplemented with 5% FBS and then left to attach overnight. When cells
reached 60–70% of confluence they were deprived of FBS 24 h previous to the assay to induce
the synchronization of cultures. Then, cells were treated with PX (Bristol-Myers Squibb,
Vicente López, Argentine), carbachol or APE (non-selective or selective M2 receptor agonist
respectively) alone or in combination in medium supplemented with 2% FBS, during 48 h in
triplicate. Also the effect of doxorubicin (Glenmark Generics S.A., Pilar, Argentine) alone or
combined with muscarinic agonists was analyzed. To inhibit the action of cholinergic agonists,
cells were previously treated with atropine at 10−9 M or methoctramine at 10−5 M (non-selec-
tive or M2 receptor selective antagonist respectively).
After treatment, to detect viable cells, the medium was replaced by 110 μl of MTT solution
that was prepared by diluting 10 μl of 5 mg/ml MTT in PBS, in 100 μl medium free of phenol
red and FBS to each well. After incubation for 4 h at 37˚C, the production of formazan was
measured by analyzing the absorbance at 540 nm with an ELISA reader (BioTek, Winooski,
USA). Values are mean ± S.E.M and results are expressed as the percentage of inhibition in
cell viability in comparison to control (cells without treatment).
ATP binding cassette transporter G2, epidermal growth factor receptor
and vascular endothelial growth factor-A detection by Western blot
Cells (2x106) were treated during three cycles of 48h/each and samples were prepared as it was
indicated to detect muscarinic receptors. Then, samples (80 μg protein per lane) were sub-
jected to 8–10% SDS-PAGE minigel electrophoresis, transferred to nitrocellulose membranes,
and incubated overnight with a rabbit anti-human ABCG2 polyclonal antibody (Santa Cruz
Biotechnology Inc., Dallas, USA) diluted 1:200, a rabbit anti-human EGFR monoclonal anti-
body (EMD Millipore-MERCK, Temecula, USA) diluted 1:1000 or a rabbit anti-human
VEGF-A polyclonal antibody (Abcam, Eugene, USA) diluted 1:1000. Then strips were incu-
bated with horseradish peroxidase-linked anti-rabbit IgG, diluted 1:10000 in TBS-T at 37˚C
for 1 h. Bands were visualized by chemiluminiscence. Quantification of the bands was per-
formed by densitometric analysis using Image J program (NIH) and was expressed as O.D.
units in comparison to the expression of GAPDH that was used as loading control [24].
Cell migration assay
To quantify the ability of tumor cells to migrate, an in vitro wound healing assay was per-
formed according to previously described methods [25]. Cells (1.5x105/well) were seeded in
24-well plates with 0.5 ml of DMEM medium supplemented with 10% FBS and left to adhere.
Then, cells were deprived of FBS to synchronize them. Then, the cell monolayer was scratched
to produce a wound with a 200 μl pipette tip, washed twice with PBS and fresh culture medium
without FBS containing different drugs was added. The migration of cells was photographed at
regular intervals from the beginning of the assay during 28 h and the uncovered area was inte-
grated with image J software (NIH). The results were expressed as the percentage of covered
area. The conditions selected, allowed us to quantify cell migration, considering negligible cell
division, since MDA-MB231 cell doubling time is longer than total experimental lasting for
each assay.
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Tumor-induced angiogenesis
Female NUDE [N-NIH Nu/Nu(spf)] mice (3 months old and 25 g/mouse) were purchased
from the animal facility of the Faculty of Veterinary Sciences, La Plata National University (La
Plata, Argentine). These animals are frequently used in xenogeneic assays with human cells.
Mice were kept under specific pathogen-free conditions following the protocol designed by
the National Institute of Health (NIH, USA) in the Guidelines for the care and handling of lab-
oratory animals (1986). They were kept in metallic cages (3 animals/cage) with a wood shaving
bedding, changed every 48 h, in 12:12 h light:dark cycle at 21±2 ºC, with water and food ad
libitum. Experimental procedures were approved by the Institutional Committee for the Care
and Use of Laboratory Animals (CICUAL) from the School of Medicine, University of Buenos
Aires (Protocol number 20020170100227BA).
Neovascularization induced by tumor cells, was analyzed using an in vivo bioassay previ-
ously described [26]. Briefly, MDA-MB231 cells were washed with PBS and detached with
trypsin, and adjusted to a concentration of 3x106 cells/ml in DMEM. Then, 0.1 ml of cell sus-
pension were injected intradermically into the area surrounding the third mammary fat pad in
each flank of mice under sterile conditions in the laboratory. Animals were treated intraperito-
neally (i.p.) 24 h post-injection of cells, with carbachol (0.94 pg/mouse) or APE (4.66 μg/
mouse) alone or in combination with PX (0.51 ng/mouse). Treatments were randomly
assigned to each animal and were administered in three doses with 48 h intervals. Atropine
(0.17 ng/mouse) or methoctramine (3.5 μg/mouse) were inoculated i.p. 20 min before other
drugs. Drugs were dissolved in PBS under sterile conditions. Doses were calculated consider-
ing the concentrations added to cells in vitro, the amount of inoculated cells and the lasting of
treatment. Each experiment includes 10 different treatments with 3 animals per treatment/
group repeated 3 times.
On day 6, animals were sacrificed by CO2 inhalation and the skin was exposed. Using a dis-
secting microscope (Konus Corporation, Miami, USA) at a 6.4 X magnification, the vascular
response was examined in the inner surface of the skin. Pictures were taken of the inoculation
sites with an incorporated digital camera (Canon Power Shot A75, Canon Inc., Lake Success,
USA). Then, the pictures were projected onto a reticular screen to count the number of vessels
per mm2 of skin. Angiogenesis was quantified as vessel density, determined by the formula: S
number of vessels in each square/total number of squares of each inoculation site [26].
EC50 calculation
Using the GraphPad Prism 6 program, dose–response data were transformed, changed to per-
centage and fitted using to a sigmoidal curve following a maximal effective concentration
(Emax) model with at least six data points. The EC50 and Emax values were obtained from
this analysis. Only data with less than 20% in the coefficient of variation for EC50 values were
considered.
Statistical analysis
Results were expressed as mean ± S.E.M. The GraphPad Prism6 computer program was used
employing one-way ANOVA analysis for paired samples to obtain the significance of differ-
ences between mean values in all control and test samples. The analysis was complemented by
using a Tukey test to compare among mean values. Differences between means were consid-
ered significant if P<0.05. The data and statistical analysis complied with the recommenda-
tions on experimental design and analysis in pharmacology [27]. When it was necessary,
values were also analyzed using Chou Talalay method to evaluate drug combination effects
[28].
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Drugs
All drugs were purchased from Sigma Chemical Co. (St. Louis, USA) unless otherwise stated.
Solutions were prepared fresh daily.
Results
Muscarinic agonists modify MDA-MB231 cell viability
In this work, we demonstrated by Western blot the expression of M1, M2, M4 and M5 receptors
in MDA-MB231 cell lysates (Fig 1). The non-tumorigenic mammary cell line MCF-10A lacks
all subtypes of muscarinic receptors (Fig 1).
In addition, we analyzed the effect of increasing concentrations of the non-selective musca-
rinic agonist carbachol added to MDA-MB231 cells in culture. Fig 2A shows that carbachol
produced an inhibition in cell viability in a concentration-dependent manner (EC50: 1.2x10-
11M). Also APE was effective to reduce tumor cell viability at concentrations higher than 10-
5M (EC50: 3.1x10-5M) (Fig 2B). Due to the absence of muscarinic receptors in non-tumori-
genic MCF-10A cells, neither carbachol nor APE modified cell viability at any concentration
tested (Fig 2A and 2B). We confirmed the cytotoxic activity of PX on breast cancer cells. In
our system, this chemotherapeutic agent produced a decrement in cell viability at
concentrations� 10-8M, when it was added to tumor cells (EC50: 8.5x10-7M). As an undesir-
able action, PX also reduced MCF-10A cell viability from10-7M (Fig 2C).
Effects produced by the combined treatment of paclitaxel with muscarinic
agonists on MDA-MB231 cells
In order to determine the ability of muscarinic agonists to synergize the action of PX on tumor
cells, we performed concentration-response curves of this drug in the presence of the EC25 of
carbachol or APE (8.6x10-12M or 1.1x10-5M respectively) to evaluate cell viability (Fig 3). The
addition of carbachol shifted to the left the dose-response curve of PX modifying the EC50
Fig 1. Muscarinic receptors´ expression. Western blot assay to detect muscarinic (M) receptor subtypes in MDA-MB231,
MDA-MB468 or MCF-10A cells. Molecular weights are indicated on the right. The expression of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) protein was used as loading control. One representative experiment of 3 is shown.
https://doi.org/10.1371/journal.pone.0226450.g001
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value by more than one order of magnitude (EC50 PX: 8.5x10-7M; EC50PX+carbachol:
1.1x10-8M) (Fig 3A). Similar results were obtained when APE was added to the concentration-
response curve of PX (EC50: PX+APE: 3.5x10-8M) on tumor cells (Fig 3B). These results and
the combination index (CI)<1 calculated by the Chou Talalay method using CompuSyn Soft-
ware (PX+carbachol: 0.10077; PX+APE: 0.13951) indicated a synergism of potentiation for
both pairs of drugs.
Taking into account the undesirable effect induced by chemotherapy at usual doses (�10-
6M), we analyzed the ability of PX at the first effective concentration (10-8M) combined with
the EC25 of carbachol or APE on the viability of tumor cells in order to mimic the dosage of
metronomic therapy (Fig 4). The combination of PX plus carbachol significantly reduced cell
viability of MDA-MB231 cells. This effect was prevented in the presence of 10-9M atropine, a
non-selective muscarinic antagonist. This combination did not exert any action on non-
tumorigenic MCF-10A mammary cells (Fig 4A). Considering that M2 receptors are expressed
in tumor cells, we analyzed the effect of the M2 selective agonist APE in combination with PX.
The addition of APE (1.1x10-5M) combined with PX potentiated the effect of PX alone to
reduce tumor cell viability (Fig 4B). The action of APE plus PX was reverted by the previous
addition of the M2 selective antagonist methoctramine (10
-5M) revealing the main participa-
tion of this receptor subtype in the reduction of tumor cell viability (Fig 4B). In addition, we
confirmed the participation of M2 receptor by pretreating cells with a specific M 2-siRNA that
prevented the action of APE plus PX on MDA-MB231 cell viability (S1 Fig). We also proved
that the addition of carbachol, APE and/or PX at the same concentrations did not modify
MCF-10A cell viability (Fig 4A and 4B).
To confirm that muscarinic agonists can synergize the action of another cytotoxic drug
reducing tumor cell viability, we tested the effect of 10-8M doxorubicin (the first effective con-
centration) a drug frequently used in breast cancer treatment combined with carbachol or
APE both at EC25 on MDA-MB231 cells (Table 1).
Either the presence of carbachol or APE potentiated the effect of doxorubicin by reducing
tumor cell viability. The effect was prevented by preincubating cells with atropine or methoctra-
mine. Moreover, in MDA-MB468 cells derived from another subtype of TN tumor, we observed
that the addition of carbachol or APE at the EC25 (1.1x10-10M or 1.3x10-7M respectively) to the
first effective concentration of PX (10-9M) was also effective to reduce cell viability. These
tumor cells also express all subtypes of muscarinic receptors (Fig 1). The addition of atropine or
methoctramine before the combined treatment significantly reduced this effect (Table 2).
We confirmed that the combination of PX at the first effective concentration plus carbachol
or APE at the EC25 added in three cycles potently reduced cell viability of MDA-MB231 cells
by more than 60%. This effect was prevented by the previous addition of atropine o methoctra-
mine respectively (Fig 5A and 5B).
In order to investigate the mechanism of action involved in the effect produced by the com-
binations, we analyzed the expression of ABCG2 and EGFR in tumor cells. The addition of PX
with carbachol (Fig 6A) or APE (Fig 6B) significantly reduced the expression of ABCG2 (PX
plus carbachol P = 0.0270; PX plus APE P = 0.0425 vs. control). The addition of carbachol,
APE or PX alone did not modify the expression of this transporter in tumor cells (Fig 6A and
6B).
Fig 2. Effect of muscarinic agonists or paclitaxel on breast cell viability. Concentration-response curves of A)
carbachol, B) arecaidine propargyl ester (APE) or C) paclitaxel on MDA-MB231 cells or MCF-10A cells. Results were
expressed as percent of inhibition in cell viability respect to control (cells without treatment). EC50: effective
concentration that produces half maximal response. Values are mean ± S.E.M. of 5 experiments performed in
duplicate. (�P<0.05; ��P<0.001;���P<0.0001 vs. control: untreated cells).
https://doi.org/10.1371/journal.pone.0226450.g002
PLOS ONE Metronomic therapy in breast cancer and M2 receptor subtype
PLOS ONE | https://doi.org/10.1371/journal.pone.0226450 September 10, 2020 8 / 20
Fig 3. Effect of muscarinic agonists on the concentration-response curve of paclitaxel. The MDA-MB231 cells were
treated with increasing concentrations of paclitaxel in the absence or presence of A) carbachol (8.6x10-12M) or B)
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It has been documented that the constitutively activation of EGFR or its transactivation
could contribute to drug resistance in different types of tumor cells [29]. As it is shown in Fig
6C, MDA-MB231 cells express this receptor and the addition of three cycles of PX plus carba-
chol significantly reduced protein expression by more than 40% in comparison to control
(P = 0.0477) (Fig 6C). Similarly, Western blot analysis showed that the treatment with APE
combined with PX also down-regulated EGFR protein by more than 41% respect to control
(P = 0.0460) (Fig 6D).
Effect produced by the combined treatment of muscarinic agonists and
paclitaxel on MDA-MB231 cell migration
Since invasion is an important step in tumor progression, we analyzed the effect of PX plus
carbachol or APE on tumor cell migration in an in vitro wound healing assay (Fig 7). At the
end of experimental time (28 h) control wound was covered by 79±8% while the addition of
PX plus carbachol or APE prevented wound covering by 42±4% or 42±6% respectively. Both
effects were reverted in the presence of atropine or methoctramine.
The combined treatment reduces vascular endothelial growth factor-A and
tumor induced-angiogenesis
Taking into account that metronomic administration of drugs can exert additional benefits in
comparison to traditional chemotherapy, we analyzed the ability of both drug combinations to
exert anti-angiogenic actions. The addition of PX plus carbachol to MDA-MB231 cells in cul-
ture for three cycles significantly down-regulated VEGF-A expression by almost 39%
(P = 0.0490) (Fig 8A). Moreover, the addition of APE to the combination exerted a similar
reduction in VEGF-A expression in MDA-MB231 cells (37±3%) (P = 0.0257) (Fig 8B). We
also analyzed the ability of MDA-MB231 cells to induce blood vessel formation in the skin of
NUDE mice (Fig 8C). The inoculation of tumor cells increased by 31±5% (P = 0.0362) skin
neovascularization in comparison to sham skin. The i.p. administration of carbachol plus PX
at metronomic doses to tumor bearers for three cycles potently reduced tumor induced-angio-
genesis. This effect was reverted when animals were treated i.p. with the non-selective antago-
nist atropine previously to the combination. Also, APE combined with PX at low doses
significantly reduced tumor neovascularization and the pre-treatment of tumor bearers with
methoctramine, a selective M2 antagonist, prevented the latter effect. Neovascular response in
the skin of tumor bearing mice treated with PX plus carbachol or APE did not differ from the
vascular density exhibited by skin obtained from sham animals (3.07±0.10). Representative
photographs of sham skin, positive neovascularized skin induced by MDA-MB231 cells (Con-
trol) and the inhibition of angiogenic response produced by the in vivo treatment of NUDE
mice with PX plus carbachol or APE are shown in Fig 8D.
Discussion and conclusions
In this work, we demonstrated for the first time, the expression of different muscarinic recep-
tor subtypes (1, 2, 4 and 5) in MDA-MB231 cells derived from a human TN mammary adeno-
carcinoma. We also observed that the long-term addition of carbachol or APE (non-selective
arecaidine propargyl ester (APE) (1.1x10-5M) during 48 h. Results were expressed as percent of inhibition in cell
viability respect to control (cells without treatment). EC50: effective concentration that produces half maximal
response. Values are mean ± S.E.M. of 5 experiments performed in duplicate. (�P<0.05; ��P<0.0001 vs. control:
untreated cells).
https://doi.org/10.1371/journal.pone.0226450.g003
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Fig 4. Effect of the combination of paclitaxel with a muscarinic agonist on breast cell viability. Cells were treated
with A) paclitaxel (PX) (10-8M) combined with carbachol (Carb) (8.6x10-12M) in the absence or presence of atropine
(AT) (10-9M) or B) PX (10-8M) was combined with arecaidine propargyl ester (APE) (1.1x10-5M) in the absence or
PLOS ONE Metronomic therapy in breast cancer and M2 receptor subtype
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and M2 receptor selective agonist, respectively) reduced cell viability in these tumor cells. Pre-
vious results from our group and also from other authors pointed to the ability of these musca-
rinic agonists to produce cell death in murine breast, bladder and neuronal tumor cells [17–
19]. These results allowed us to consider muscarinic receptors as specific therapeutic targets
for the treatment of breast tumors, in particular TN since they are classified as very aggressive
and malignant. Previous reports indicated that TN tumor bearers benefit from the addition of
PX in the adjuvant therapy, supporting the conclusion that taxanes are useful for this group of
patients [5, 30]. Our results confirmed the ability of PX to decrease TN breast tumor cell viabil-
ity, but it also produced similar actions on normal MCF-10A breast cells as an undesirable
effect. The latter is one of the reasons why specific adjuvant regimens for TN breast cancer are
still under revision, and third generation chemotherapy regimens utilizing dose dense or met-
ronomic poly-chemotherapy are thought to be more effective and less harmful than traditional
chemotherapy. Considering the latter, together with our previous findings in MCF-7 cells that
were sensible to a low dose metronomic therapy focused on muscarinic receptors [16] we
designed a metronomic administration of PX plus muscarinic agonists at low concentrations.
This strategy, besides focusing on muscarinic receptors as novel targets for the treatment of
TN tumors, could be less aggressive for normal mammary cells that lack of these receptors [2,
12]. Moreover, our results reveal the possibility of generalizing the usage of this combination
of drugs since it is also effective when PX is replaced by doxorubicin. It is also important to
consider that the administration of PX plus carbachol or APE is effective on MDA-MB468
cells, derived from a different TN tumor than MDA-MB231 classified as Basal A with ampli-
fied EGFR [31].
It is important to note that M2 receptor mediates the main cytotoxic action of this low dose
combined therapy, since similar results were obtained by replacing carbachol with APE, a
selective M2 agonist, in the combination. The participation of this receptor subtype was con-
firmed by preventing the effect of the combination either with the selective M2 antagonist
presence of methoctramine (MET) (10-5M). Results are expressed as percent of inhibition in cell viability respect to
control (cells without treatment). Values are mean ± S.E.M. of 5 experiments performed in duplicate. (�P<0.01;
��P<0.001; ���P<0.0001 vs. control, PX or Carb).
https://doi.org/10.1371/journal.pone.0226450.g004
Table 1. Effect of the combination of doxorubicin with a muscarinic agonist on MDA-MB231 cell viability.
MDA-MB231
Treatment Cell Viability (% of Inhibition)
DX + Carb 35.3±0.8 ��
DX + Carb + AT -6.7±2.1
Carb 11.2±3.2 �
DX 12.4±4.6 �
DX + APE 33.3±2.1 ��
DX + APE + MET -7.7±2.6
APE 12.2±3.9 �
Cells were treated with doxorubicin (DX) (10-8M) combined with carbachol (Carb) (8.6x10-12 M) or with arecaidine
propargyl ester (APE) (1.1x10-5 M) during 48 h in the absence or presence of atropine (AT) (10-9M) or
methoctramine (MET) (10-5M) respectively. Results are expressed as cell viability (% of inhibition) respect to control
(cells without treatment). Values are mean ± S.E.M. of 5 experiments performed in duplicate.
�P<0.001
��P<0.0001 vs. control (cells without treatment).
https://doi.org/10.1371/journal.pone.0226450.t001
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methoctramine or by transfecting cells with a specific M2-siRNA. In line with our findings,
similar effects were demonstrated in human glioblastoma cell lines and in glioblastoma cancer
stem cells [19, 20].
One of the most important side effects of traditional chemotherapy is the resistance to
drugs. In fact, the most commonly observed mechanism conferring drug resistance in cancer
cells is the over-expression of ABC transporters that mediates the efflux of endogenous and
exogenous substances using energy provided by ATP hydrolysis. ABCG subfamily plays piv-
otal roles in the transport of anticancer drugs out of cells, generating the development of drug
resistance [32]. Here we analyzed the expression of ABCG2 since this protein is expressed in
CD44+/CD24- stem cell population that is abundant in MDA-MB231 tumor. The ABCG2
expression was potently down-regulated by the combination of PX either with carbachol or
with APE. In relation with our results, Farhana et al. reported that malignancy of colon cancer
cells induced by bile acids promotes cancer stemness in colonic epithelial cells by up-regulat-
ing M3 receptor together with ABCG2 expression [33].
Several aggressive tumors present an overexpression of the HER2 marker considering it a
target in cancer therapy [34, 35]. A variant with high homology to this marker is the EGFR
which is also over-expressed in cancer [36, 37]. Its expression and/or activity can be modulated
by muscarinic receptors [38]. Several authors consider that the sole up-regulation of EGFR
expression is a bad prognosis marker and an indicator of chemoresistance in TNBC patients
or cell lines [39–41]. Our results demonstrated that the combination of PX plus carbachol or
APE drastically reduced EGFR expression in tumor cells and this effect should be beneficial in
the treatment of this type of tumor. Recently, it has been described that the inhibition of EGFR
activity in glioblastomas produces a decrement in drug resistance activity mediated by the
ATP-dependent membrane transporter, ABC [42]. Although we only evaluated a down-regu-
lation in the expression of EGFR due to drug treatment, more experiments could be useful to
evaluate its activity in our system.
It should be important to consider that, the reduction in cell viability produced by the com-
bination of PX with carbachol or APE could be related to a decrement in the number of cancer
stem cells which are present at very high levels in TN tumors and are generally positive to
ABCG2 transporter as it was previously reported [43, 44]. In addition, the over-expression/
Table 2. Effect of the combination of paclitaxel with a muscarinic agonist on MDA-MB468 cell viability.
MDA-MB468
Treatment Cell Viability (% of Inhibition)
PX + Carb 33.4±2.5 ��
PX + Carb + AT -1.0±1.9
Carb 11.6±2.8 �
PX 13.8±2.7 �
PX + APE 26.9±3.6 ��
PX + APE + MET 11.6±5.5
APE 9.1±2.2 �
Cells were treated with paclitaxel (PX) (10-9M) combined with carbachol (Carb) (1.2x10-10 M) or with arecaidine
propargyl ester (APE) (1.4x10-7M) during 48 h in the absence or presence of atropine (AT) (10-9M) or
methoctramine (MET) (10-5M) respectively. Results are expressed as cell viability (% of inhibition) respect to control
(cells without treatment). Values are mean ± S.E.M. of 5 experiments performed in duplicate.
�P<0.001
��P<0.0001 vs. control (cells without treatment).
https://doi.org/10.1371/journal.pone.0226450.t002
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Fig 5. Effect of the combination of paclitaxel with a muscarinic agonist on breast cell viability administered in
three cycles. Cells were treated with A) paclitaxel (PX) (10-8M) combined with carbachol (Carb) (8.6x10-12M) in the
absence or presence of atropine (AT) (10-9M) or B) PX (10-8M) was combined with arecaidine propargyl ester (APE)
(1.1x10-5M) in the absence or presence of methoctramine (MET) (10-5M). Results are expressed as percent of
inhibition in cell viability respect to control (cells without treatment). Values are mean ± S.E.M. of 4 experiments
performed in duplicate. (�P<0.05; ��P<0.01���P<0.001; ����P<0.0001 vs. control, PX or Carb).
https://doi.org/10.1371/journal.pone.0226450.g005
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activation of EGFR leads to VEGF-A production and is closely related to the proliferative
behavior of breast cancer cells as well as tumor endothelial cells [45].
Invasion and/or migration are the most important steps in tumor progression since they
are linked to metastasis and aggressiveness that are usually observed in TN breast cancer
patients. Our results show for the first time the ability of low dose combined therapy to reduce
tumor cell migration targeting M2 receptor. In addition, angiogenesis has been broadly consid-
ered as a switch-on mechanism in tumor growth and metastasis. One of the additional benefits
of metronomic therapy to be tested is its ability to reduce tumor-induced angiogenesis [46].
Here we confirmed that the treatment of TN tumor cells with the combination of PX plus mus-
carinic agonists is able to reduce the expression of VEGF-A, and also the in vivo neovascular
response induced by tumor cells. The treatment of tumor cells with the combination of PX
plus muscarinic agonists produced a decrement in VEGF-A levels in vitro. We cannot discard
that the anti-angiogenic actions observed in vivo could also be due to a decrement in the num-
ber of tumor cells, or to a down-regulation of other angiogenic factors produced by tumor
cells and/or by stromal cells. More experiments are needed to clarify these aspects in our
model.
Fig 6. Expression of ATP binding cassette G2 transporter and epidermal growth factor receptor in MDA-MB231 cells. The expression of ATP binding
cassette G2 (ABCG2) and epidermal growth factor receptor (EGFR) in tumor cells was analyzed by Western blot. Cells were treated for three cycles with
paclitaxel (PX) (10-8M) combined with A) and C) carbachol (Carb) (8.6x10-12M) or with B) and D) arecaidine propargyl ester (APE) (1.1x10-5M) in the
absence or presence of atropine (AT) (10-9M) or methoctramine (MET) (10-5M). Molecular weights are indicated on the right. Densitometric analysis of
the bands was expressed as optical density (O.D.) units relative to the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) protein used as
loading control. One representative experiment of 3 is shown (�P<0.05 vs. control).
https://doi.org/10.1371/journal.pone.0226450.g006
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In conclusion, our results demonstrate that low doses therapy combining PX with a non-
selective or a selective M2 agonist could be a useful strategy to treat TN breast tumors. In par-
ticular, the treatment focused on M2 receptor appears as a new promising therapeutic target to
counteract not only breast cancer cell survival, but also to reduce invasion and pathological
neo-angiogenesis, suggesting a possible prevention of chemoresistance by reducing ABCG2
and EGFR expression.
Fig 7. Effect of the combination of paclitaxel with a muscarinic agonist on MDA-MB231 cell migration. Cell migration
was evaluated as the percentage of covered area after 28 h of treatment with A) paclitaxel (PX) (10-8M) combined with
carbachol (Carb) (8.6x10-12M) in the absence or presence of atropine (AT) (10-9M) or B) PX (10-8M) combined with
arecaidine propargyl ester (APE) (1.1x10-5M) in the absence or presence of methoctramine (MET) (10-5M). C)
Representative photographs (64X) were obtained by phase contrast at the beginning (0h) and at the end of experimental time
(28 h). Values are mean ± S.E.M. of 3 experiments performed in duplicate. (�P<0.05; ��P<0.01; ���P<0.0001 vs. control;
#P<0.001 vs. each drug added alone).
https://doi.org/10.1371/journal.pone.0226450.g007
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Supporting information
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S1 Fig. Muscarinic subtype 2 receptor expression silencing. A) Western blot assay to detect
muscarinic (M) receptor subtype 2 in MDA-MB231 cells in the absence or presence of NC-
siRNA or M2-siRNA. Molecular weights are indicated on the right. Densitometric analysis of
the bands is expressed as optical density (O.D.) units relative to the expression of glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) protein used as loading control. One representa-
tive experiment of 3 is shown. (�P<0.01 vs. cells without M2-siRNA). B) Effect of the
combination of paclitaxel (PX) (10-8M) with arecaidine propargyl ester (APE) (1.1x10-5M) in
Fig 8. Tumor induced angiogenesis. To analyze the expression of vascular endothelial growth factor-A (VEGF-A) by Western blot,
MDA-MB231 cells were treated with A) paclitaxel (PX) (10-8M) combined with carbachol (Carb) (8.6x10-12M) or B) with arecaidine propargyl
ester (APE) (1.1x10-5M) in the absence or presence of atropine (AT) (10-9M) or methoctramine (MET) (10-5M) respectively. Molecular weights
are indicated on the right. Densitometric analysis of the bands was expressed as optical density (O.D.) units relative to the expression of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) protein used as loading control. One representative experiment of 3 is shown. C) In vivo
neovascularization induced by MDA-MB231 cells in NUDE mice skin. Cells were inoculated as it was stated in Methods, and drugs were
administered i.p. Values are mean ± S.E.M. of 3 experiments performed with 3 animals per group inoculated in both flanks. D) Representative
photographs of mice skin from sham animals or inoculated with tumor cells (Control) without treatment or treated with PX+Carb or PX+APE.
Magnification 6.4X. (#P<0.05 vs. sham skin; �P<0.05 vs. control).
https://doi.org/10.1371/journal.pone.0226450.g008
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the absence or presence of M2-siRNA. Results are expressed as percent of inhibition in cell via-
bility respect to control (cells without treatment). Values are mean ± S.E.M. of 3 experiments
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